Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Next Science Ltd ( (AU:NXS) ) just unveiled an update.
Shareholders of Next Science Limited have overwhelmingly approved all resolutions put to a general meeting held on 28 January 2026, including a return of capital and the company’s delisting from the Australian Securities Exchange, with each resolution passed by poll with more than 99% of votes cast in favour. The strong support for the capital return and delisting formalises the company’s transition following the 2025 sale of substantially all of its assets to OSARTIS GmbH, marking a decisive step in winding down its listed-company structure and returning value to investors as it exits the public market.
The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited is an Australian-listed medical technology company that previously focused on products targeting biofilm-based infections. In September 2025 it completed the sale of substantially all of its assets, along with those of its wholly owned subsidiaries, to OSARTIS GmbH, a Demetra company, and has since applied to be removed from the official list of the ASX.
Average Trading Volume: 525,971
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.